Condition: Recurrent or Metastatic Nasopharyngeal Carcinoma · Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.
This description comes directly from the study's public registry record.
MediLink Study Team · +86 512 62858368 · clinicaltrials@medilinkthera.com
Always discuss trial participation with your own doctor first.
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Not Yet Recruiting |
| Zhangzhou Municiple Hospital of Fujian Province | Zhangzhou, Fujian, China | Not Yet Recruiting |
| Dongguan People's Hospital | Dongguan, Guangdong, China | Not Yet Recruiting |
| Affiliated Cancer Hospital and Institute of Guangzhou Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | Not Yet Recruiting |
| Yuebei People's Hospital | Shaoguan, Guangdong, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Guilin Medical University | Guilin, Guangxi, China | Not Yet Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07258979